Comparative Pharmacology
Head-to-head clinical analysis: HY PAM 25 versus SERPASIL ESIDRIX 1.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HY PAM 25 versus SERPASIL ESIDRIX 1.
HY-PAM "25" vs SERPASIL-ESIDRIX #1
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydroxyzine pamoate is a piperazine antihistamine that acts as a histamine H1-receptor antagonist, thereby suppressing histamine-mediated responses in the skin and mucous membranes. Additionally, it exhibits anxiolytic and sedative properties through central nervous system depression via inhibition of subcortical regions.
Reserpine depletes catecholamines (norepinephrine, dopamine) from central and peripheral nerve endings by irreversibly inhibiting the vesicular monoamine transporter (VMAT2), leading to reduced sympathetic outflow and vasodilation. Hydrochlorothiazide inhibits the Na+-Cl- symporter in the distal convoluted tubule, reducing sodium and water reabsorption.
25 mg orally once daily, preferably at bedtime, for short-term treatment of insomnia.
1 tablet orally twice daily, titrate to response. Each tablet contains reserpine 0.1 mg and hydrochlorothiazide 25 mg.
None Documented
None Documented
Terminal elimination half-life 6-8 hours in healthy adults; prolonged to 12-18 hours in renal impairment (CrCl <30 mL/min) and in elderly patients.
Reserpine: 50-100 hours (terminal); clinical effects persist due to irreversible adrenergic neuron blockade. Hydrochlorothiazide: 6-15 hours (terminal).
Primarily renal (60-70% unchanged drug), with 30-40% biliary/fecal elimination as metabolites.
Reserpine: renal (30% as metabolites, <1% unchanged), fecal (60% as metabolites). Hydrochlorothiazide: renal (>95% unchanged).
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination